Liminatus Pharma, Inc. LIMN
Liminatus Pharma, Inc. (Nasdaq: LIMN) is an oncology drug developer. Its lead program, IBA101 (Hu3A5 anti-CD47 monoclonal antibody), is in Pre-clinical for advanced solid cancers including NSCLC. Its next catalyst on record is IBA101: Phase 1 clinical trial start (scheduled) (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IBA101 — Phase 1 clinical trial start (scheduled) (2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IBA101 (anti-CD47 mAb) | advanced solid cancers / NSCLC | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.